ConductScience.org, home

Paper33657296

Diffuse Large B-Cell Lymphoma.

Sehn LH and 1 other. N Engl J Med, 2021. Cited by 1,002 papers, by iCite.

Cite this record

ConductScience Library. Diffuse Large B-Cell Lymphoma. Papers, record 33657296. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33657296

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Diffuse Large B-Cell Lymphoma.
PubMed
Journal
N Engl J Med
PubMed
Year
2021
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
1,002
iCite
Relative citation ratio, by iCite
58
iCite
Revised in PubMed
2021-08-21
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Sehn LHLaurie H
2Salles GGilleshttps://orcid.org/0000-0002-9541-8666

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic AgentsMajor topic
Immunotherapy, AdoptiveMajor topic
Lymphoma, Large B-Cell, DiffuseMajor topic
Algorithms
Combined Modality Therapy
Humans
Neoplasm Staging
Prognosis
Risk Factors
Stem Cell Transplantation
Transplantation, Autologous

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
P30 CA008748NCI NIH HHSUnited StatesP30CA008748PubMed and NIH

Source NIH RePORTER

Download CSV of grants

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in34107188Diffuse Large B-Cell Lymphoma.https://conductscience.org/library/papers/34107188

Source PubMed

Download CSV of comments and corrections

References81

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
131868632
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.
Lancet2019https://conductscience.org/library/papers/31868632PubMed
216754935Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.J Clin Oncol2006https://conductscience.org/library/papers/16754935PubMed
329713087Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes.Nat Med2018https://conductscience.org/library/papers/29713087PubMed
431157579Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma.J Clin Oncol2019https://conductscience.org/library/papers/31157579PubMed
528774879Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.Blood2017https://conductscience.org/library/papers/28774879PubMed
627382104Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736.J Clin Oncol2016https://conductscience.org/library/papers/27382104PubMed
730617197Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL.Blood2019https://conductscience.org/library/papers/30617197PubMed
829414277Post-Transplantation Lymphoproliferative Disorders in Adults.N Engl J Med2018https://conductscience.org/library/papers/29414277PubMed
933211842Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma.Blood2021https://conductscience.org/library/papers/33211842PubMed
1030380386CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma.N Engl J Med2018https://conductscience.org/library/papers/30380386PubMed
1124264230An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era.Blood2014https://conductscience.org/library/papers/24264230PubMed
1212075054The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.N Engl J Med2002https://conductscience.org/library/papers/12075054PubMed
1332888407Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.Lancet2020https://conductscience.org/library/papers/32888407PubMed
1429672223Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials.J Clin Oncol2018https://conductscience.org/library/papers/29672223PubMed
1528426350
Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
J Clin Oncol2017https://conductscience.org/library/papers/28426350PubMed
1628862883Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.J Clin Oncol2017https://conductscience.org/library/papers/28862883PubMed
1727382100CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP.J Clin Oncol2016https://conductscience.org/library/papers/27382100PubMed
189647875Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma.N Engl J Med1998https://conductscience.org/library/papers/9647875PubMed
1932289277A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications.Cancer Cell2020https://conductscience.org/library/papers/32289277PubMed
2031498031Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium.J Clin Oncol2019https://conductscience.org/library/papers/31498031PubMed

See all 81 referencesDownload CSV of references

Cited by747

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1,002 citations.

PMIDTitleJournalYearIn PapersSource
42972012The cyclin-G associated kinase (GAK) is a clinically actionable drug target required for mitosis in diffuse large B-cell lymphoma.Leukemia2026https://conductscience.org/library/papers/42972012PubMed
42939957Plasma IgG N-Glycosylation as a Novel Biomarker of Disease Severity and Prognosis in Diffuse Large B-Cell Lymphoma, Not Otherwise Specified.Biomedicines2026https://conductscience.org/library/papers/42939957PubMed
42936799Myocardial Infarction with Non-obstructive Coronary Arteries; Diffuse Large B-Cell Lymphoma Presenting as an Acute Coronary Syndrome.Arch Acad Emerg Med2026https://conductscience.org/library/papers/42936799PubMed
42930590
Baseline Tumor Transcriptional Features and Event-Free Survival After Anti-CD19 CAR T-Cell Therapy with Axicabtagene Ciloleucel in Large B-Cell Lymphoma: An Exploratory Reanalysis of the Randomized ZUMA-7 Trial.
Med Sci (Basel)2026https://conductscience.org/library/papers/42930590PubMed
42928836CD20-Positive B-Cell Non-Hodgkin Lymphoma Associated With Recurrent Acute Pancreatitis, Bilateral Renal Lesions, and Retroperitoneal Lymphadenopathy.Cureus2026https://conductscience.org/library/papers/42928836PubMed
42910135Associations of Subcutaneous and Visceral Fat Areas with Progression-Free Survival in Patients with Diffuse Large B-Cell Lymphoma.Int J Med Sci2026https://conductscience.org/library/papers/42910135PubMed
42890318Zanubrutinib monotherapy in CD79B-mutated relapsed or refractory diffuse large B-cell lymphoma: A multicenter Phase 2 study.Hemasphere2026https://conductscience.org/library/papers/42890318PubMed
42889486Spatial immune ecosystems and therapy resistance in large B-cell lymphoma: from single-cell multi-omics to immunotherapy-matched validation.Front Immunol2026https://conductscience.org/library/papers/42889486PubMed
42882397From Divergent Pathogenesis to Precision Medicine: The Road to Targeted Therapy in HIV-Associated and HIV-Unrelated Diffuse Large B-Cell Lymphoma.Diagnostics (Basel)2026https://conductscience.org/library/papers/42882397PubMed
42882057Analysis of Treatment Patterns and Outcomes Among Patients with Third-Line or Later (3L+) Diffuse Large B-Cell Lymphoma (DLBCL) with Multiple Qualifying Index Dates Treated in the United States.J Clin Med2026https://conductscience.org/library/papers/42882057PubMed
42881024Comorbidity Burden and Prognosis in Patients Aged 80+ Years With Large B-Cell Lymphoma.Clin Lymphoma Myeloma Leuk2026https://conductscience.org/library/papers/42881024PubMed
42871809Therapeutic potential of oncolytic viruses in hematopoietic malignancies: from preclinical insights to clinical realities.Front Microbiol2026https://conductscience.org/library/papers/42871809PubMed
42852632Resistance to covalent Bruton's tyrosine kinase inhibitors in diffuse large B‑cell lymphoma: Molecular mechanisms and therapeutic implications (Review).Int J Oncol2026https://conductscience.org/library/papers/42852632PubMed
42813078Primary Diffuse Large B-cell Lymphoma of the Urinary Bladder: A Case Report and Narrative Review of Treatment Modalities and Clinical Outcomes.Cureus2026https://conductscience.org/library/papers/42813078PubMed
42812805Tracheostomy Before Polatuzumab Vedotin-Containing Therapy for Airway-Threatening Cervical Diffuse Large B-Cell Lymphoma: A Case Report of Two Patients.Case Rep Hematol2026https://conductscience.org/library/papers/42812805PubMed
42801263Diffuse Large B-Cell Lymphoma Presenting as an Infiltrative Masticator Space Lesion Mimicking Inflammatory Disease: A Case Report.Cureus2026https://conductscience.org/library/papers/42801263PubMed
42798844Macrophage phagocytosis checkpoints in DLBCL immunotherapy: an evidence-maturity framework from CD47 to CD200.Front Oncol2026https://conductscience.org/library/papers/42798844PubMed
42795255Late-Onset Neutropenia and Hypogammaglobulinemia After Dose-Adjusted R-EPOCH in Unfavorable Diffuse Large B-Cell Lymphoma.Life (Basel)2026https://conductscience.org/library/papers/42795255PubMed
42793820Is There a Tumor Proportion Score Threshold at Which Tumor-Cell PD-L1 Adds Prognostic Information Beyond the International Prognostic Index in Large B-Cell Lymphoma?Diagnostics (Basel)2026https://conductscience.org/library/papers/42793820PubMed
42782785Establishment of Patient-Derived Xenotransplant and Cell Line Models for Canine B-Cell Lymphoma.Cells2026https://conductscience.org/library/papers/42782785PubMed

See all 747 cited byDownload CSV of cited by

Genes47

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ABCB610058PubTator's text mininghttps://conductscience.org/library/genes/10058NCBI Gene
ADGRE230817PubTator's text mininghttps://conductscience.org/library/genes/30817NCBI Gene
ALB213PubTator's text mininghttps://conductscience.org/library/genes/213NCBI Gene
ALK238PubTator's text mininghttps://conductscience.org/library/genes/238NCBI Gene
BCL2596PubTator's text mininghttps://conductscience.org/library/genes/596NCBI Gene
BCL6604PubTator's text mininghttps://conductscience.org/library/genes/604NCBI Gene
BCR613PubTator's text mininghttps://conductscience.org/library/genes/613NCBI Gene
BTK695PubTator's text mininghttps://conductscience.org/library/genes/695NCBI Gene
CCR11230PubTator's text mininghttps://conductscience.org/library/genes/1230NCBI Gene
CCR2729230PubTator's text mininghttps://conductscience.org/library/genes/729230NCBI Gene
CD19930PubTator's text mininghttps://conductscience.org/library/genes/930NCBI Gene
CD22933PubTator's text mininghttps://conductscience.org/library/genes/933NCBI Gene
CD27429126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
CD28940PubTator's text mininghttps://conductscience.org/library/genes/940NCBI Gene
CD3029936PubTator's text mininghttps://conductscience.org/library/genes/9936NCBI Gene
CD4920PubTator's text mininghttps://conductscience.org/library/genes/920NCBI Gene
CD47961PubTator's text mininghttps://conductscience.org/library/genes/961NCBI Gene
CD79A973PubTator's text mininghttps://conductscience.org/library/genes/973NCBI Gene
CD79B974PubTator's text mininghttps://conductscience.org/library/genes/974NCBI Gene
CD8A925PubTator's text mininghttps://conductscience.org/library/genes/925NCBI Gene

See all 47 genesDownload CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/33657296

GET https://conductscience.org/api/papers/v1/33657296/references?page=2